第二次高强度聚焦超声(HIFU)治疗对首次治疗后未达满意效果的良性甲状腺结节的作用
本研究评估第二次HIFU消融对首次治疗后6个月体积缩小未超过50%的良性甲状腺结节的有效性和安全性。28例患者接受第二次HIFU治疗,6个月平均体积缩小率仅21.78±16.87%,仅2例(7.1%)达到治疗成功,但梗阻症状评分较基线显著改善,且第二次治疗前结节体积较大是体积缩小率较大的显著因素。
要点
- 首次HIFU后6个月体积缩小未达50%的良性甲状腺结节,第二次HIFU治疗后6个月平均体积缩小率仅21.78±16.87%。
- 第二次治疗后6个月仅2例(7.1%)达到治疗成功(体积缩小率>50%),9例(32.1%)体积缩小率<10%。
- 梗阻症状评分从基线3.96±1.04显著改善至6个月2.58±1.39(p<0.001),且体积缩小率与症状改善显著相关(ρ=0.438,p=0.025)。
核心结论
- 第二次HIFU治疗后主观梗阻症状持续改善,但结节实际缩小程度较小;第二次治疗前结节体积较大者体积缩小更显著。
研究设计与样本
- 研究纳入28例首次HIFU治疗后6个月体积缩小未超过50%的良性甲状腺结节患者,均接受第二次HIFU治疗,在基线、3个月和6个月行超声测量结节体积。
诊断标准与关键数值
- 治疗成功定义为体积缩小率(VRR)>50%,VRR=[基线体积-6个月体积]/基线体积×100%;第二次治疗后6个月平均VRR为21.78±16.87%,中位数(范围)为16.16(1.63-54.07)%。
临床应用与阅片要点
- 第二次HIFU治疗后6个月仅2例(7.1%)达到治疗成功,9例(32.1%)VRR<10%;梗阻症状VAS评分从基线3.96±1.04改善至3个月2.96±1.43(p<0.001)和6个月2.58±1.39(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: We aimed to assess the efficacy and safety of second high-intensity focused ultrasound (HIFU) ablation treatment in benign thyroid nodules that had failed to shrink by > 50% 6 months after the first treatment.
METHODS: Twenty-eight patients who did not achieve 50% volume reduction at 6 months after the first HIFU treatment underwent a second HIFU treatment. Nodule volume was measured on ultrasound at baseline, 3 months and 6 months. Extent of nodule shrinkage (by volume reduction ratio) (VRR) = [Baseline volume - volume at 6 months]/[Baseline volume] * 100. Treatment success was defined as VRR > 50%. Obstructive symptom score (by 0-10 visual analogue scale, VAS) was evaluated for 6 months after treatment.
RESULTS: No complications occurred after the second treatment. The mean 6-month VRR was 21.78 ± 16.87% with a median (range) of 16.16 (1.63-54.07)%. At 6 months, only two (7.1%) patients achieved treatment success, while nine (32.1%) patients had VRR < 10%. However, relative to baseline (3.96 ± 1.04), the mean VAS significantly improved at 3 and 6 months (2.96 ± 1.43, p<0.001 and 2.58 ± 1.39, p<0.001, respectively). There was a significant correlation between VRR and improvement in VAS score at 6 months (ρ=0.438, p=0.025). Greater nodule volume before the second treatment (OR=1.169, 95% CI=1.004-1.361, p=0.045) was a significant factor for greater VRR after the second treatment.
CONCLUSIONS: Although subjective obstructive symptoms continued to improve after the second treatment, the actual extent of nodule shrinkage was small. Larger-volume nodules tended to shrink more significantly than smaller-volume nodules in the second treatment.
KEY POINTS: • Second treatment resulted in small shrinkage in unsatisfactory nodules after first treatment. • Obstructive symptoms tended to continue to improve after second treatment. • Larger-size nodules tended to respond better in the second treatment.
引用
- Lang BH, Woo YC, Chiu KW, et al. Role of second high-intensity focused ultrasound (HIFU) treatment for unsatisfactory benign thyroid nodules after first treatment. Eur Radiol. 2018. PMID: 30088067. doi:10.1007/s00330-018-5671-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。